Skip to content

Study · Randomized controlled trial · n = 51 · 2009

3 results

Absence of QTc prolongation in a thorough QT study with subcutaneous liraglutide, a once-daily human GLP-1 analog for treatment of type 2 diabetes.

Chatterjee DJ, Khutoryansky N, Zdravkovic M, Sprenger CR, Litwin JS

Journal of clinical pharmacology8 Sept 2009Cited by 42 (Europe PMC)

PMID19737980 (opens in a new tab)DOI10.1177/0091270009339189 (opens in a new tab)PepBankPUB-19737980
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialSafety outcome

    In 51 healthy participants, the upper bound of the 1-sided 95% confidence interval for the placebo-subtracted QTc change with liraglutide was below 10 ms for all 4 correction methods.

    In plain wordsIn healthy people, liraglutide did not lengthen the heart QTc interval compared with placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeQTc interval, upper bound of placebo-subtracted change
    Study

    n = 51

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    1.8 mg once daily (highest dose period) · subcutaneous · 7 days per doseAs given in this study (human).

    Measurements

    upper bound of 95% CI, placebo-subtracted QTc change
    < 10 ms
    all 4 correction methods

    Source sentences

    Summary
    The upper bound of the 1-sided 95% confidence interval for time-matched, baseline-corrected, placebo-subtracted QTc intervals was <10 ms for all 4 correction methods.
    1 context sentence
    Summary · context
    In this randomized, placebo-controlled, double-blind crossover study, 51 healthy participants were administered placebo, 0.6, 1.2, and 1.8 mg liraglutide once daily for 7 days each.
  2. 02HumanRandomized controlled trialSafety outcome

    In healthy participants, liraglutide showed no concentration-exposure dependency on QTc interval changes.

    In plain wordsIn healthy people, higher liraglutide levels in the blood did not change the QTc interval more.

    Peptide
    Liraglutide
    Outcome
    No significant changeQTc change versus liraglutide concentration
    Study

    n = 51

    Outcome group
    Heart function · Cardiovascular
    Studied dose
    0.6, 1.2 and 1.8 mg once daily · subcutaneous · 7 days per doseAs given in this study (human).

    Source sentences

    Summary
    There was no concentration-exposure dependency on QTc interval changes by liraglutide
    1 context sentence
    Summary · context
    In this randomized, placebo-controlled, double-blind crossover study, 51 healthy participants were administered placebo, 0.6, 1.2, and 1.8 mg liraglutide once daily for 7 days each.
  3. 03HumanRandomized controlled trialSafety outcome

    In healthy participants given liraglutide, no QTc values above 500 ms and no QTc increases above 60 ms occurred.

    In plain wordsIn healthy people given liraglutide, no extreme QTc values or large QTc increases were seen.

    Peptide
    Liraglutide
    Outcome
    No significant changeQTc above 500 ms or increase above 60 ms
    Study

    n = 51

    Outcome group
    Heart function · Cardiovascular
    Studied dose
    0.6, 1.2 and 1.8 mg once daily · subcutaneous · 7 days per doseAs given in this study (human).

    Source sentences

    Summary
    no QTc thresholds above 500 ms or QTc increases >60 ms.
    1 context sentence
    Summary · context
    In this randomized, placebo-controlled, double-blind crossover study, 51 healthy participants were administered placebo, 0.6, 1.2, and 1.8 mg liraglutide once daily for 7 days each.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 1NCT01516255

Effect of Liraglutide on Heart Frequency in Healthy Volunteers

Novo Nordisk A/Sn = 64Jul 2006 to Nov 2006

Diabetes · Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 25 Jan 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.